Department of Biomodelling, Novo Nordisk A/S, Maaloev, Denmark. tkt@novonordisk.com
Abstract:
Introduction
Recombinant activated factor VII (rFVIIa) has been used as adjunctive therapy in trauma patients with severe bleeding. However, its pharmacokinetics profile remains unknown.